Joshua Fitch, Senior Editor

The ACIP committee voted to pass both resolutions to update its recommendation on the hepatitis B vaccine for infants.

"For those not receiving the HBV birth dose, it is suggested that the initial dose is administered no earlier than 2 months of age," reads part of vote 1.

A look back at the FDA submissions and regulatory decisions in the pediatric health care space from November 2025.

Take a quick look at everything you may have missed this month, including the top FDA approvals and latest clinical updates.

“It represents the first time an in vivo HSC-directed gene insertion therapy has been evaluated in a patient," said CEO Jim Burns in a statement.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

Learn simple strategies to help picky eaters enjoy a balanced Thanksgiving meal through planning, involvement, and a relaxed holiday atmosphere.

The investigational compound centanafadine to treat ADHD in children, adults, and adolescents, is a first-in-class NDSRI.

The clearnace was granted to the Ceribell System for electrographic seizure detection in newborns pre-term and older.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

A phase 1b study of zelpultide alfa demonstrated a favorable safety profile and encouraging early reductions in BPD and ventilation duration, supporting advancement to a pivotal international Phase 2b/3 program.

The CDC website now claims "studies supporting a link [between vaccines and autism] have been ignored by health authorities."

The agency approved a monthly dosing option for select patients acorss all approved indications, including wAMD, DME, DR, and RVO.

“This label expansion helps close a long-standing gap in the treatment of pediatric patients with hereditary antithrombin deficiency,” said George M. Rodgers, III, MD, PhD.

The target action date for roflumilast cream 0.3% for plaque psoriasis in children 2 to 5 years is set for June 29, 2026.

Fifteen infants with suspected or confirmed infant botulism and a confirmed exposure to Byheart Whole Nutrition infant formula have been reported from 12 states.

Long-term analysis of the PEDFIC studies presented at NASPGHAN 2025 demonstrated sustained reductions in bile acids and pruritus with odevixibat in FIC1 deficiency.

At NASPGHAN 2025, investigators presented 52-week safety data from an ongoing phase 3 trial of linaclotide, the first approved treatment for patients aged 7 and older with IBS-C.

FDA approves first irritable bowel syndrome with constipation (IBS-C) treatment, linaclotide (Linzess), for children aged 7 years and older based on pediatric and adult trial data.

A look back at the FDA submissions and regulatory decisions in the pediatric health care space from October 2025.

If approved, this UC indication would add to pediatric indications of ustekinumab for psoriasis and active psoriatic arthritis.

Take a quick look at everything you may have missed this month, including the top FDA approvals and latest clinical updates.

The AAP encourages pediatricians to use shared decision-making with families inquiring about leucovorin while providing clear information about available evidence and potential risks.

The FDA has assigned a target action date of February 28, 2026, for a potential expanded indication of pegvaliase-pqpz to include adolescents with PKU.

A pair of phase 3 trials showed that AbbVie's daily upadacitinib 15 mg led to a 50% reduction in T-VASI 50 and a 75% reduction in F-VASI 75 at 48 weeks among adolescents 12 years and older.

In this Q&A, nurse practitioner Tracey Gaslin, PhD, discusses tick bites in pediatric patients, from how to prevent a bite to what to do after a bite, and highlights resources available from the Fight the Bite initiative.

Key highlights from the conference included public health, advocacy for vaccines, and artificial intelligence.

Zoliflodacin study investigator Sarah McLeod, PhD, highlights data presented at IDWeek 2025 in this Q&A with Contemporary Pediatrics.

New one-year data showed that baricitinib continued scalp, eyebrow, and eyelash regrowth in adolescents with severe alopecia areata.